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Objective: To evaluate the costs and benefits of various anti-smoking policy alternatives including 
taxation and four cessation programs, accounting for the demographic projections in 2011-2050 in 
Turkey.  
Methods: Demographic projections are combined with incidence and mortality rates of four major 
cigarette related diseases, price elasticity of cigarette demand and unit costs of nonprice measures to 
reduce demand in order to estimate the net present discounted values of policy alternatives. 
Results: Among policy alternatives that yield the same amount of cigarette consumption, cessation 
programs yield lower costs to households and the society at large than taxation, while taxation is 
preferred by the public sector. Net benefit to the public sector as a function of the tax rate is a single-
peaked Laffer curve. The public sector can obtain the highest net benefit if it raises the special 
consumption tax rate from its current level by nearly 9 percentage points.  
Conclusion: Although intervention programs emerge as the preferred anti-smoking alternatives, more 
research is needed on estimating the cost-effectiveness and social desirability of taxation and 
intervention programs in Turkey.  
 
Turkey has become one of the major consumers of 
cigarettes with nearly 16 million adult smokers and 
as the 10
th in the world in terms of the amount of 
tobacco products consumed (MoH, 2010).  
Demographic projections of the Turkish 
population point to a substantial increase in the 
number of smokers within the next 40 years, unless 
smoking prevalence declines. Such an increase will 
undoubtedly lead to a surge in healthcare 
expenditures and a drop in productivity and income 
tax revenue. In the literature on the economics of 
smoking, government intervention is recommended 
for several reasons including the existence of 
externalities (such as environmental tobacco smoke 
(ETS) or the financial burden of smokers on non-
smokers) and information problems about the 
health consequences of smoking (such as 
addiction). (See, for example, Warner, Chaloupka, 
Cook, et al., 1995; Ross, Chaloupka, 2002.)  
Since the 1990s, Turkish governments have 
enacted several laws to regulate smoking. However, 
with an overall smoking rate of 31% and a 
declining average age of uptake, cigarette 
consumption is still a major health problem in 
Turkey (MoH, 2010).  Clearly, it is essential that 
effective tobacco control policies be implemented 
without delay to discourage smoking and to reduce 
prevalence especially among young people.  
In this study we present a detailed analysis of 
the costs and benefits of various anti-smoking 
policy alternatives including taxation and four 
different smoking cessation programs. The impacts 
of these policies on the public sector, households, 
and the whole society are estimated for a simulation 
period of 2011-2050, using the expected 
demographic transition of Turkey. One of our main 
findings is that the function that relates the public 
sector’s net benefit to the tax rate on cigarettes is a 
single-humped Laffer curve. The prevailing tax rate 
on smoking is suboptimal for both the public sector 
and the society as a whole. Therefore, policy 
intervention in the form of higher cigarette prices 
seems correct, although at the expense of further 
increasing net household cost. Another contribution 
is our comparison, in terms of the induced net 
benefits, of taxation with the smoking cessation 
programs. We consider two distinct anti-smoking 
plans and four intervention programs within each 
plan. For each anti-smoking plan, we adjust the tax 
rate on cigarettes to compensate for the reduction in 
the tax revenues due to the planned decrease in the 
number of smokers, and calculate the costs and 
benefits of each program. Next, we compare these 
compensated intervention programs to purely 
taxation-based policy alternatives. We say that a 
change in the tax rate on cigarettes is ‘equivalent’ to an intervention program if they yield the same 
total quantity of cigarette consumption over the 
simulation period. We show that for both target 
plans the estimated operating costs of the 
compensated programs are much lower than 
induced costs of ‘equivalent’ tax rates incurred by 
smokers. Households prefer cessation programs; 
however, as expected, the public sector prefers 
taxation due to its higher net benefits. Since under 
higher tax rates net costs to households always 
outweigh net benefits of the public sector, cessation 
programs are preferred by the society as a whole as 
well.   
There are only a few studies on smoking in 
Turkey; no comprehensive analyses of the costs and 
benefits of smoking and of various anti-smoking 
policies exist. Bilir and Onder (2000) estimated the 
effect of the ban on smoking in public places based 
on survey data. Onder (2002), Onder, Yurekli 
(2007) and Yurekli, Onder, Elibol, et al. (2010) 
estimated price elasticity of cigarette demand and 
showed by simulation that the government could 
increase total tax revenues by increasing taxes. The 
few studies that have been conducted on other 
countries use micro-level survey data in a particular 
year and base their estimates on the concept of 
smoking attributable fraction (SAF).  (See, for 
example, Sung, Wang, Jin, et al, 2006; John, Sung, 
Max, 2009).  
Our study takes a different path. Instead of 
individual level expenditure data, our estimates are 
based on more meso-level variables. We conduct a 
more detailed analysis using variables such as the 
estimated incidence and mortality rates of smoking 
related diseases, the projected numbers of smokers 
and quitters and the predicted days of absenteeism 
from work. We compare policy options. A major 
contribution of our study is that we run simulations 
for a 40-year time frame, which enables us to 




We estimate the extent to which the costs and 
benefits of smoking in Turkey will change during 
the period of 2011-2050 in response to alternative 
tobacco control policies. To this end, we follow the 
expenditure-based cost analysis approach (see 
Lightwood et al., 2000), which defines costs and 
benefits as monetary expenditures and revenues that 
occur because of tobacco use. Intangible costs are 
excluded, as is the economic value of lost life or the 
monetary value of suffering due to a smoking-
related illness. The cost and benefit items included 
are explained in detail later in this section.  
To measure the impacts of alternative tobacco 
control policies, we consider a dynamic simulation 
model that uses projections of smoking prevalence, 
keeping in mind the demographic transition of the 
country. For details on all data sources and 
methods, please see the Appendix.   
Demographic transition 
Turkey’s population, which was 72,698 million in 
2010, is expected to increase by about 10.4% in 10 
years to reach 80,257 million by year 2020. Within 
the following decades, the growth rate of the 
population is expected to taper off; the estimates are 
7.9% in 2020-2030, 5.7% in 2030-2040 and 3.2% 
in 2040-2050. The decline in the growth rate of 
population is expected to change the age 
decomposition of the country. This is the well-
known demographic transition that many countries, 
including those in Eastern Europe and the Former 
Soviet Union, have been going through. (Chawla, 
Betcherman, Banerji, 2007).  
Turkey is a young country. As of 2010, 51.9% 
of the population is younger than 30 years old. The 
30-60 year old group constitutes 38% of the 
population. But the population is expected to get 
older in time. The share of the 0-30 year old group 
is expected to go down from 46.6% in 2020 to 
35.5% by 2050. Meanwhile, the share of the 45-60 
year old group is expected to rise from 15.5% in 
2010 to 19% in 2050. The share of the 60-75 year 
old group is projected to rise from 7.4% in 2010 to 
17.9% by year 2050. 
   
Cigarette consumption  
Cigarette consumption in Turkey went up by 
80.95% between years 1990 and 2000. While 
population growth was partly responsible, the more 
important reason was the increase in per capita 
consumption (Onder, 2002).  
We observe that smoking is more common 
among men than women, and among the young and 
the middle aged than the elderly. Among adult 
males, 48.8% are current smokers, 16.8% are 
quitters and 34.4% are never smokers. The 
corresponding figures for adult females are 12.8%, 
5.2% and 82%. Among adult males, 51.7% of 18-
34 year olds, 50.2% of 35-64 year olds and 26.5% 
of 65+ year olds are current smokers. The 
corresponding figures for adult females are 17.9%, 
10.9% and 1.4%. (Can, Çakırbay, Topbaş, et al., 
2007 and OECD Health Data 2009.)  
Figure 1: Projected number of smokers during 
2011-2050 
 
Source: Authors’ calculations.  
 
The number of smokers is related to both the 
prevalence of smoking within age groups and the 
shares of the age groups. We assume that (with no 
change in tobacco control policies) smoking 
prevalence will remain the same in time within each 
age group (as specified above). Figure 1 shows the 
estimated number of smokers in years 2011-2050 
under this assumption. 
 
Incidence and mortality rates of some smoking-
related diseases  
It is well-known that incidence and mortality rates 
of some diseases are substantially higher among 
smokers than non-smokers. In our study, we take 
lung cancer, chronic obstructive pulmonary disease 
(COPD), chronic cardiovascular disease (CVD) and 
stroke as the most prominent diseases that are 
associated with smoking and for which data are 
available.  
In order to estimate the costs incurred due to 
these diseases while incorporating the effects of 
demographic change, we need to know the 
incidence and mortality rates for age groups, 
differentiated by smoking status. We estimate these 
rates by using: (1) number of smokers, quitters and 
never-smokers by sex and age group, (2) incidence 
and mortality rates of smoking-related diseases by 
age group, (3) risk ratios by smoking status, sex and 
age group.  
Based on the estimated incidence and mortality 
rates by sex, age group and smoking status, we 
estimate the number of new cases and deaths. In 
Figure 2 we plot the logarithms of these numbers. 
 
Figure 2: Estimated numbers of new cases and 







    Source: Authors’ calculations. 
 
Costs and benefits 
For each cost or benefit item, the total amount is 
computed as the present discounted value of the 
amounts in years 2011-2050. The discount rate is 
the real interest rate in Turkey in 2010 (1.5%).  
 
1.  Expenditures for illness and income loss from 
premature death of smokers due to smoking: 
To estimate the expenditures for illness in each 
year, we multiply the estimated number of new 
cases of the four diseases by the per case treatment 
costs of these diseases. Expected cost to the public 
sector is 84% (the share of the public sector in total 
health expenditures) of this total.  
By using the expected number of deaths in each 
year, we estimate the expected total income loss 
assuming that people who died prematurely could have worked until age 65 and earned an average 
salary.  
 
2. Productivity loss due to absenteeism of smokers 
and non-smokers: 
Studies have shown that absenteeism and work 
related accidents are more common among smokers 
than non-smokers. We estimate total productivity 
loss by multiplying the estimated sex-specific 
additional number of annual absent days among 
smokers relative to non-smokers, by the sex-
specific employment rates and by the average 
employment cost per day.  
We know that ETS can be as damaging as 
occasional smoking. We estimate total productivity 
loss by multiplying the estimated sex-specific 
additional number of sick days among non-smokers 
exposed to ETS relative to those who are not 
exposed to ETS, by the sex-specific employment 
rates and by the average employment cost per day.  
In both cases, tax loss is estimated by 
multiplying the productivity loss by the average 
income tax rate. 
 
3. Costs of tobacco control policies: 
We assume that implementing taxation is 
costless and that the tax elasticity of cigarette prices 
is 100%, i.e., any change in the tax rate affects the 
price at the same rate. 
We consider two anti-smoking plans,  with 
distinct target prevalence rates. For each plan, we 
evaluate four smoking intervention programs.   
‘Class’, ‘Contest’ and ‘Self-Help’ are borrowed 
from Altman, Flora, Fortmann (1987). These are 
community-based programs that were used between 
1981 and 1983 in the Stanford Five City Project. 
‘Class’ included sessions on quitting techniques, 
‘Contest’ entitled the right to attend a lottery with 
several prizes, and ‘Self-Help’ contained some 
practical tools to support quit attempts. The quit 
rates for ‘Class’, ‘Contest’ and ‘Self-Help’ were 
35%, 22% and 21% respectively.  The per-quitter 
costs of these programs are 698.64, 382.23, and 
126.57 in 2010 USD, respectively.  
The fourth intervention, ‘Awareness’, is 
borrowed from Stevens, Thorogood, Kayıkkı 
(2002). This program, which included a play, a 
poster and media campaign, and purpose-designed 
leaflets, was used between 1996 and 1997 in 
London in a Turkish community with a population 
around 8,500. The 1-year quit rate for this program 
is around 2.9%. The average cost per quitter, after 
adjusting for inflation and exchange rate, is 1,631 
USD. 
Given a smoking prevalence target (of 25% or 
20%), we estimate the expected number of quitters 
in each campaign year. We multiply these estimates 
with the 1-year per-quitter cost of each intervention 
program to calculate thereby the discounted sum of 
annual operating costs over the campaign period.  
4. Tax revenues from cigarette sales: 
To calculate the estimated tax revenue, we multiply 
the estimated number of smokers by the average per 
smoker consumption (304.31 packages per year), 
by average price of cigarettes (3.41 USD in 2010, 
including taxes) and by the average tax rate in each 
year. The average tax rate on smoking in Turkey is 
composed of the special consumption tax (SCT) 
and the value added tax (VAT), which were 63.4% 
and 15.3% in 2010, respectively.  
 
Aggregating costs and benefits 
We look at three aggregate measures:  We define 
‘net public benefit’ as the tax revenues from 
cigarette sales net of the sum of publicly financed 
expenditures for illness of smokers due to smoking, 
income tax loss from premature death of smokers 
due to smoking, income tax loss associated with 
productivity loss due to absenteeism, and cost of 
tobacco control policies in effect. To evaluate the 
social impacts of the alternative tobacco control 
policies, we also define ‘net household cost’ as the 
sum of publicly non-financed part of expenditures 
for illness of smokers due to smoking, after-tax 
income loss from premature death of smokers due 
to smoking, productivity loss (net of income tax) 
due to absenteeism, and tax revenues of the public 
from cigarette sales; and ‘net social cost’ as the 
difference between “net household cost” and “net 
public benefit”.  
 
RESULTS 
Effects of tax increases 
For our simulations, we fix the VAT rate at its 2010 
level (15.3%). As we vary SCT rate from 0.0% to 
75.8%, the total tax on cigarettes as a percentage of 
tax-included retail selling price ranges between 
15.3 and 91.1. Given the current prevalence of 
smoking, we calculate for each tax rate the resulting 
number of smokers in each simulation year and 
their total cigarette consumption, using the tax 
(price) elasticity of smoking prevalence (-20%)   
borrowed from Onder, Yurekli (2007) and assumed to be fixed in the simulation period. The results in 
Table 1 show that public cost, net social cost and 
cigarette consumption are decreasing functions of 
the tax rate. But, the relationship between net public 
benefit and the tax rate on cigarettes is a left-
skewed and single-hump shaped Laffer curve.  
When the tax rate is at 15.3%, public cost due to 
smoking exceeds tax revenues. Net public benefit is 
positive only for tax rates between 40.3% and 
91.1%.  For the status quo in Turkey where the tax 
rate is 78.7%, net public benefit over the period 
2011-2050 is a strikingly high figure yet found to 
be suboptimal. Net public benefit reaches its 
maximum of 384,636 million USD at the tax rate of 
84.5%, which, if implemented, would imply a 
drastic increase of the SCT from its current level of 
63.4% to 69.2%. We should notice that cigarette 
consumption under the current tax rate significantly 
falls to 171,392 million packages under the optimal 
tax rate. Finally, net public benefit becomes zero 
when the tax rate is 91.1%. We should note that the 
change in the average price of cigarettes with 
respect to its 2011 level is 37.4% at the public’s 
optimal tax rate and as high as 139% when the tax 
rate reaches 91.1%. Due to a high price elasticity of 
cigarette consumption, the nearly four-fold 
difference in price variation over a very narrow 
interval of tax rates leads to the dramatic tax 
sensitivity of net public benefit over the right tail of 
the Laffer curve.   
 
Effects of smoking intervention programs 
Next, we consider two alternative plans to reduce 
smoking prevalence to targeted rates by 2016. In 
both plans, average per-smoker consumption is 
assumed to remain the same. The first plan aims to 
decrease the ratio of smokers in the population from 
30.6% to 25%, by reducing the number of smokers 
by 3.9% each year. The second plan is more 
ambitious as the number of smokers decline by 
8.0% each year, creating a prevalence rate of 20% 
by 2016.  
We combine each target plan with a tax hike so 
as to compensate for the tax loss caused by the 
reduction in the number of smokers. The tax 
increase required to keep tax revenues intact is 
2.9% for the first plan and 5.8% for the second. 
These tax adjustments lead to an increase in the 
average cigarette price by 16.0% and 37.8% for the 
first and second plans, respectively.  
Given these compensation schemes, we 
estimate, for each plan, costs and benefits under 
four alternative intervention programs. Our 
simulation results reported in Table 2 show that the 
five-year discounted costs of the compensated 
intervention programs are quite low under both 
plans (about 0.01%-0.11% of 2010 Turkish GDP 
for the first plan and 0.02%-0.20% for the second). 
For comparison, total health expenditures were 
about 5.9% of GDP in 2010. We observe that total 
cigarette consumption over 2011-2050 reduces to 
189,086 million packages and to 154,034 million 
under the first and second plans, respectively. Net 
social cost declines by 9%-10% for the first plan 
and by 18%-19% for the second plan.  
To compare the effects of compensated smoking 
intervention programs to those of purely taxation-
based policy options, we calculate for each target 
plan the unique tax rate that would - in the absence 
of any intervention programs - yield the same total 
quantity of cigarette consumption as the programs 
over 2011-2050, as reported in item (9) of Table 2. 
This consumption-equalizing tax rate is found to be 
83.0% and 85.7% for the first and second target 
plans, respectively. We observe that for both plans, 
net social cost due to smoking is significantly lower 
under intervention programs than under 
consumption-equalizing taxation, simply because of 
the greater induced reductions, under intervention 
programs, in items (1a), (1b) and (2) of Table 2.  
The public sector, unlike the society at large, 
prefers purely taxation-based anti-smoking plans to 
intervention programs. This preference does not 
arise, however, without an enlarged conflict of 
interest between the households and the public 
sector. Taxes collected under equivalent taxation 
are higher by 9.5% and 8.7% than in the first and 
second target plans, respectively; evidently raising 
both net public benefit and net household cost 
drastically. 6 
 
Table 1: Costs and benefits under different tax rates on cigarettes (million USD) 
  
  Tax rate on cigarettes (%) 
  15.3 25.3 35.3 40.3 50.0 60.0 70.0 78.7 80.0 84.5 90.0 91.1 
(1a) Expenditures for illness of smokers 
due to smoking 
62,852 62,561 62,179 61,941 61,342 60,420 58,884 56,374 55,811 53,135 46,594 44,345 
(1a’) Publicly financed expenditures for 
illness of smokers due to smoking  
52,796 52,551 52,231 52,030 51,527 50,753 49,462 47,354 46,881 44,633 39,139 37,250 
(1b) Income loss from premature death of 
smokers due to smoking 
327,667 326,355 324,639 323,566 320,869 316,721 309,808 298,512 295,981 283,938 254,500 244,381 
(1b’) Income tax loss from premature 
death of smokers due to smoking  
65,533 65,271 64,928 64,713 64,174 63,344 61,962 59,702 59,196 56,788 50,900 48,876 
(2) Productivity loss due to absenteeism   50,474 50,439 50,393 50,364 50,292 50,182 49,998 49,697 49,629 49,308 48,524 48,254 
(2’) Income tax loss associated with 
productivity loss due to absenteeism  
10,095 10,088 10,079 10,073 10,058 10,036 10,000  9,939  9,926  9,862  9,705  9,651 
(3) Cost of tobacco control policies  0 0 0 0 0 0 0 0 0 0 0 0 
(4) Tax revenues from cigarette sales  44,622  71,801  106,107 126,817 176,374 245,632 342,299 449,766 465,264 495,918 271,224  95,777 
(5) Public cost   128,424 127,910 127,237 126,816 125,759 124,133 121,423 116,996 116,003 111,283  99,743  95,777 
(6) Net public benefit   -83,802 -56,109 -21,130  0  50,615 121,499 220,875 332,770 349,261 384,636 171,481  0 
(7) Net household cost  357,190 383,246 416,081 435,871 483,118 548,822 639,564 737,353 750,682 771,017 521,099 336,981 
(8) Net social cost  440,992 439,355 437,211 435,871 432,503 427,323 418,689 404,583 401,421 386,381 349,618 336,981 
(9) Cigarette consumption (million 
packages)  
338,696 333,679 327,112 323,007 312,689 296,818 270,368 227,153 217,467 171,392  58,764  20,050 
 
Notes: (1a’)=0,84*(1a) ,  (1b’)=0.20*(1b),  (2’)=0.20*(2),  (5)= (1a’)+ (1b’)+(2’)+(3),  (6)=(4)-(5),  (7)=(1a)-(1a’)+(1b)-(1b’)+(2)-(2’)+(4),  (8)=(7)-(6).   














Target Plan I (Smoking Rate = 25%) 
 














































































































(1a) Expenditures for illness of smokers due 





(1a’) Publicly financed expenditures for 
illness of smokers due to smoking 
47,354 41,144 45,497 35,426 43,787 
(1b) Income loss from premature death of 
smokers due to smoking 
298,512 265,467 288,563 235,013 279,401 
(1b’) Income tax loss from premature death 
of smokers due to smoking 
59,702 53,093 57,713 47,003 55,880 
(2) Productivity loss due to absenteeism 
49,697 48,820 49,432 48,012 49,187 
(2’) Income tax loss associated with 
productivity loss due to absenteeism 
9,939 9,764 9,886 9,612 9,837 
(3) Cost of tobacco control policies  0  1,673 916  303 3,907  0  3,045  1,666 552 7,108  0 
(4) Tax revenues from cigarette sales  449,766 449,766 492,564 449,766 489,010 
(5) Public cost  116,996 105,675 104,917 104,305 107,909 113,096  95,076  93,697  92,582  99,139  109,504 
(6) Net public benefit  332,770 344,090 344,848 345,461 341,857 379,468 354,691 356,070 357,184 350,627 379,505 
(7) Net household cost  737,353 709,033 771,625 682,934 760,221 
(8) Net social cost  404,583 364,942 364,184 363,572 367,175 392,157 328,244 326,865 325,750 332,307 380,715 
(9) Cigarette consumption (million 
packages) 
227,153 189,086 189,086 154,034 154,034 
Notes: The compensating tax rate that keeps tax revenues from cigarette sales intact under four intervention programs is 81.6% for the first target plan and 84.5% for the second plan. The tax rate that yields the same 
cigarette consumption as the smoking intervention programs do is estimated to be 83.0% for the first target plan and 85.7% for the second plan.  
CONCLUSION 
The demographic transition in Turkey is predicted 
to generate a rapid increase in the number of 
smokers in the next four decades. Simulations of 
the costs and benefits of various tobacco control 
policies show that smoking cessation programs in 
which tax revenues are kept constant by the help of 
tax increases yield lower costs to households than 
the purely taxation-based policy alternatives that 
yield the same quantities of cigarette consumption. 
Furthermore, estimated net benefits of compensated 
smoking cessation programs are higher for the 
society at large, rendering these programs the 
socially more desirable policy option.    
Another finding of this paper is that the 
optimization of net public benefit  implies an 
increase of the SCT rate from its current level by 
almost 6 percentage points, raising the tax rate from 
78.7% to 84.5% and consequently the average price 
of cigarettes from 3.41 USD (5.30 TL) to 4.68 USD 
(7.28 TL). The current Turkish tax rate is the 16
th 
highest in the EU. The same rate applies in the 
Netherlands, where the average retail price of a 
pack of cigarettes is 6.36 USD (4.73 €). We also 
note that the highest tax rate (91.1%) the Turkish 
government can charge (and still achieve positive 
net public benefit) is close to the rate charged by 
the UK (90.14%), where the average price is 8.42 
USD (5.44 £). Apparently, there seems to be a large 
room to reduce smoking in Turkey by taxation. 
We should note that we make two assumptions: 
First, we assume that price increases do not affect 
average consumption of non-quitters, since we do 
not know how smoking intensity is related to 
incidence and mortality rates. Second, we assume 
that intervention programs have no effect on the 
average cigarette consumption (as well as illness, 
mortality, and absenteeism) of non-quitters among 
participants, as there are no reported estimates of 
these effects in the literature. It is possible that the 
two assumptions balance each other to keep the 
social ranking of taxation and intervention 
programs the same. However, one factor that 
clearly strengthens the support for purely taxation-
based anti-smoking plans is that we are likely to 
underestimate the costs of operating countrywide 
programs by simply replicating small community-
based programs, assuming away resource 
constraints and technical challenges. Such concerns 
definitely encourage further research in designing 
and implementing countrywide interventions, with 
the collaboration of the public health authority, to 
reduce smoking in Turkey. 
    We should finally note that the estimation 
method we suggest in this paper can be used to 
study the cases in other developing countries where 
incidence and mortality rate data differentiated by 
smoking status are not available.  
   
What this paper adds 
 
Previous literature on tobacco control policies in 
Turkey lacks a thorough economic analysis of 
alternative anti-smoking policies. 
This study evaluates, from the viewpoints of the 
public sector, households, and the society at large, 
the costs and benefits of several policy options 
including tax increases on cigarettes on one side 
and four smoking cessation programs on the other 
side. Our simulations show that taxation is 
preferred by the public sector, while smoking 
cessation programs are more desirable for 
households and the society at large. Moreover, we 
find that in Turkey, net public benefit from taxation 
of smoking is a Laffer curve, where the optimal tax 
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APPENDIX: Data sources and methods 
 
1) Projections of the population and the number of smokers 
 
a) Population projections: 
 
TURKSTAT up to year 2025. Between 2025-2050, growth rate 
projections of the United Nations. (Source: United Nations 
Department of Economic and Social Affairs, Population 
Division, http://esa.un.org/unpp/ index.asp). 
 
b) Smoking rates and the number of smokers by smoking status, 
sex and age groups: 
 
Can, Çakırbay, Topbaş, et al. (2007), with an adjustment to 
match the overall smoking rate in OECD Health Data 2009. 
Number of smokers in 2011-2050 = (smoking rates) x (projected 
population in the corresponding sex and age groups). 
  
2) Hazard ratios by sex, age group and smoking status 
 
Data from Thun, Louis, Henley (2000). The reported hazard 
ratios show the risk of death relative to never smokers. 
  
3) Incidence and mortality rates for 18-34, 35-64 and 65+ age  
groups 
 
Obtained from different data sources. Usually the source studies 
use slightly different age groups, requiring some adjustments to 
be made.   
a) Lung cancer: Ferlay, Bray, Pisani  et al. (2004), Turkish data. 
 
b) Chronic obstructive pulmonary disease (COPD): Incidence 
rates for EURO B1 group that includes Turkey, from Shibuya, 
Mathers, Lopez (2001). Mortality data are from MoH (2006). 
 
c) Chronic cardiovascular disease (CVD): Turkish data from 
Onat (2009) for Turkey.  
 
d) Stroke: Country averages from Sarti, Stegmayr, Tolonen et al. 
(2003).  
  
4) Incidence and mortality rates by sex, age group and 
smoking status: estimation method 
To differentiate the rates in item 3 according to smoking status, 
we assume that the rates reflect the risk for smokers and quitters 
relative to never smokers, similar to the hazard ratios in Thun, 
Louis, Henley (2000). Let us define a to f as the number of 
people by smoking status in a particular sex-age group, as in the 
table below.  
 




Number of new 
cases/deaths  a c  e 
Number of healthy 
people  b d  f 
 
What we can estimate are: 
-Hazard  ratio of smokers: HRs= (a⁄(a+b )) ⁄ (e⁄(e+f )) 
-Hazard  ratio of quitters: HRq = (c/(c+d))/(e/(e+f)) 
-Within each sex-age group, the ratio of the number of smokers 
to never smokers, (a+b)/(e+f); the ratio of the number of quitters 
to never smokers, (c+d)/(e+f). 
-Within each sex-age group, the total number of new cases/ 
deaths,  X= a+c+e, estimated as the incidence/ mortality rate 
times the population in the corresponding sex-age group.  
 
Knowing the above, we calculate a, c and e. Incidence/ mortality 
rates by sex, age and smoking status groups are estimated by 
dividing a, c and e by the population in the corresponding sex, 
age and smoking status group.  
 
5) Treatment costs of diseases 
The treatment cost of lung cancer is 11,850 USD per case (in 
2010 prices), adjusted using Edis and Karlikaya (2007). The 
costs of COPD, CVD and stroke are 3,068 USD, 1,923 USD, 
and 4,213 USD, respectively (Hacettepe Universitesi 2005, 
2006). The cost of CVD is the average of the per-case treatment 
costs of unstable angina and myocardial enfarction. The cost of 
COPD is per exacerbation. The estimated number of 
exacerbations is calculated as the expected number of cases 
multiplied by 0.4596 (the share of Level II patients), by 0.0807 
(the share of Level III and IV patients) (Buist, McBurnie, 
Vollmer, 2007) and by 2 (the median number of exacerbations 
(Miravitlles, Mayordomo, Artes, 1999)).  
The public share of health expenditures is 84%, which is taken 
from TURKSTAT’s Life Satisfaction Survey.  
6) Tax loss due to premature death 
We take into account the sex-specific employment rates and the 
average income tax rate to estimate the amount of taxes that 
could have been collected on earnings. Employment rates for 
women (22.3%) and men (60.7%) are from TURKSTAT, 2009 
Household Labor Force Survey. Average gross earnings by sex 
and age group are from TURKSTAT, 2006 The Structure of 
Earnings Survey. The average income tax rate is 20% (Ministry 
of Finance, budget revenue statistics). Income earned until 
retirement is estimated as the present discounted value of annual 
expected incomes until age 65.  
7) Tax revenues 
Average cigarette consumption is based on total consumption 
data from Tobacco and Alcohol Market Regulatory Authority 
and our estimate of the number of smokers.  The average price of 
cigarettes, 5.30 TL (3.41 USD) per pack in 2010 prices, is from 
TURKSTAT price statistics. The tax rate on cigarettes, 78.7%, is 
from the Ministry of Finance.  
 
8) Productivity loss due to absenteeism and environmental 
tobacco smoke 
Tsai, Wen, Hu et al. (2005, Table 1) report that absenteeism 
among male (female) smokers is 1.06 (1.21) days higher 
compared to non-smokers. Tsai, Wen, Hu et al. (2005, Table 3) 
report that sick days among ETS exposed male (female) non-
smokers is 0.79 (0.96) days higher compared to those who are 
not exposed to ETS.  
9) The annual discount rate for the period 2011-2050 
 




10) The GDP and the total expenditures on health in Turkey  
 
GDP in 2010 is 1,106,486  million TL  (711,521 million USD). 
The total expenditures on health is 57,740 million TL in 2008, 
which we inflation-adjusted to 2010 prices as 42,137 USD. 
Source: TURKSTAT  
 
11) US inflation between 1981-2011 
 
153,13% (CPI published by US Bureau of Labor Statistics) 
Source: www.bls.gov  
 
12) UK inflation between 1998-2011 
 
27,67% (CPI published by UK National Statistics) 
Source: www.statistics.gov.uk 
 
13) Cigarette tax rates and tax included average retail prices 
in the EU 
 
Source: European Commission Directorate General Taxation and 
Customs Union, Ref 1032, March 2011.  
http://ec.europa.eu/taxation_customs/taxation/excise_duties 
/index_en.htm 